CLINICAL ROLE -
Treatment of SCC With Immune Checkpoint Inhibitors Evolves
New data have resulted in updated guidelines for neoadjuvant cemiplimab.
X-7/7 Trial Data May Change Prescribing Practices in Metastatic Breast Cancer
The single institution study compared fixed dose capecitabine to standard dose capecitabine to compare efficacy and tolerability in metastatic breast cancer.
NATALEE Trial Results Add Ribociclib to CDK4/6 Inhibitor Options in Early-Stage Breast Cancer
The benefit of ribociclib was seen as consistent against all of the stratification factors in the phase III study.
INDIGO Trial Provides First Randomized Data Supporting Use of IDH Inhibitor in Patients With IDH1/2 Mutating Gliomas
Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.
Phase 3 ADAURA Trial Non-small Cell Lung Cancer Survival Results Provide Impactful Data, But Questions for Practice Setting Remain
Panelists discuss the potential impact of the study data presented at the ASCO 2023 Annual Meeting, which led to significant response from the field.
Expert: Ensuring Access to Oncology Drugs in Community Cancer Centers Is Crucial
Andre Harvin, PharmD, MBA, discussed the use of immunotherapies in melanoma and broader challenges with access to oncology care in rural or underserved communities.
BCMA-Targeted Therapies Take Multiple Approaches in Multiple Myeloma
Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.
Two ASCO Abstracts May Transform Metastatic Castration Resistant Prostate Cancer Treatment in First-Line Setting
The ASCO abstracts were on the TALAPRO-2 trial (abstract 5053) and PROpel trial (abstract 5012).
After Decades of Limited Treatment Options, New Treatments Are Showing Promise for Non-Melanoma Skin Cancer
With immune checkpoint inhibitors in particular, patients are seeing greater results with fewer adverse effects.
Treatment of SCC Using Immune Checkpoint Inhibitors Has Evolved in Recent Years
For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.
New Therapies Show Significant Efficacy in Breast Cancer
Both immunotherapies and targeted therapies are showing significant promise in these areas, offering patients new treatment options.
New Breast Cancer Treatments See Significant Obstacles With Affordability, Access
Andrea Iannucci, PharmD, BCOP, assistant chief pharmacy officer at UC Davis Health, discussed challenges and opportunities when implementing new treatments for breast cancer.
Expert: Immunotherapies, Targeted Therapies Show Promise in Melanoma
Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.
Oncology Pharmacists Connect Meeting Promises Clinical Updates, Opportunities to Advance Patient Care
The meeting aims to bring together pharmacists to discuss solutions for responding to the rapidly evolving evidence and needs for effective implementation.
Oncology Pharmacists Connect Meeting Promises Focus on Changing Treatment Paradigms, Implementation Challenges for Pharmacists
Program Chair Ryan Haumschild, PharmD, MS, MBA, discussed what attendees can look forward to at the inaugural Oncology Pharmacists Connect meeting.
2 Clarke Drive Cranbury, NJ 08512